Do you want to read an article? Please log in or register.
Clinical Determinants of Successful Omalizumab Therapy in Severe Allergic Asthma Patients: 4-Year-Long, Real-Life Observation
Asthma
RECOMMENDED
Related content
RECOMMENDED
Asthma
Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Puggioni F, Brussino L, Canonica GW, Blasi F, Paggiaro P, Caminati M, Latorre M, Heffler E, Senna G, Severe Asthma Network in Italy (SANI) group.
doi: 10.2147/JAA.S274245
Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety
Respir Med.
Mansur AH, Srivastava S, Mitchell V, Sullivan J, Kasujee I
doi: 10.1016/j.rmed.2017.01.008.
Asthma
Real-life Efficacy of Omalizumab After 9 Years of Follow-up
Allergy Asthma Immunol Res.
Menzella F, Galeone C, Formisano D, Castagnetti C, Ruggiero P, Simonazzi A, Zucchi L
doi: 10.4168/aair.2017.9.4.368.
Asthma
Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study
Allergy Asthma Immunol Res.
Li J, Kang J, Wang C, Yang J, Wang L, Kottakis I, Humphries M, Zhong N; China Omalizumab Study Group
doi: 10.4168/aair.2016.8.4.319.
COMMENTED
Duration of the efficacy of omalizumab after treatment discontinuation in 'real life' severe asthma
Thorax.
Vennera MDC, Sabadell C, Picado C; Spanish Omalizumab Registry
doi: 10.1136/thoraxjnl-2017-
RECOMMENDED
Allergic Respiratory Diseases
Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Allergy Clin Immunol Pract
Bousquet J, Humbert M, Gibson PG, Kostikas K, Jaumont X, Pfister P, Nissen F
doi: 10.1016/j.jaip.2021.01.011
Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study)
BMJ Open.
Niven RM, Saralaya D, Chaudhuri R, Masoli M, Clifton I, Mansur AH, Hacking V, McLain-Smith S, Menzies-Gow A.
doi: 10.1136/bmjopen-2016-011857
Asthma
Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria
Clin Exp Allergy.
Hew M, Gillman A, Sutherland M, Wark P, Bowden J, Guo M, Reddel HK, Jenkins C, Marks GB, Thien F, Rimmer J, Katsoulotos GP, Cook M, Yang I, Katelaris C, Bowler S, Langton D, Wright C, Bint M, Yozghatlian V, Burgess S, Sivakumaran P, Yan KY, Kritikos V, Peters M, Baraket M, Aminazad A, Robinson P, Jaffe A, Powell H, Upham JW, McDonald VM, Gibson PG
doi: 10.1111/cea.12774.
RECOMMENDED
Asthma
Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma
J Allergy Clin Immunol.
Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, Barros M, Buhl R, Howarth P, Albers FC, Bradford ES, Gilson M, Price RG, Yancey SW, Ortega H
doi: 10.1016/j.jaci.2018.09.033.